Background: Poor quality drugs include substandard and counterfeit medicines. Poor quality antibiotics selectively kill the susceptible strain and leaves resistant strain to multiply. Metronidazole is a broad spectrum antibiotic whose effectiveness depends up on a dose administered to the patient. Objective: The aim of the study is to assess the quality of different brands of metronidazole Benzoate oral suspension available in Jimma town, West Ethiopia. Methods: Cross-sectional study was conducted in Jimma town, West Ethiopia from Feb 08 – Mar 28, 2018. The assay result of all the seven brands of Metronidazole Benzoate oral suspensions was entered to statistical package for social sciences software version 24.0 for windows. Then, one way analysis of variance was performed using Tukey test to determine whether there exists significant difference in assay result of the brands (p<0.05). Result: All the seven Metronidazole benzoate oral suspensions assessed in this study passed British Pharmacopoeia 2013 specification of identity test of the drug. All the brands passed the assay test and total aerobic microbial count specification United States Pharmacopoeia 2015. The highest percentage of drug content was obtained for Metrolag, 105.56%, while the least content for Mizel, 93.12%. However, statistical comparison of drug contents at 95% confidence interval indicates that there is significant difference in drug content within and among the seven brands of Metronidazole benzoate oral suspensions (p<0.05). The pH of all the brands was with in United States Pharmacopoeia 2015 specification limit.

Introduction: In economic terms the costs may be classified as touchable and untouchable. The touchable costs are given for a relative easiness to be measured and quantified too. At present health context one of the items with more research needs respect to the economic impact is the smoking. Objective: To describe the main touchable costs related to smoking as risk factor. Methods: Was made a descriptive research about the main touchable costs related to smoking as risk factor. As teoricals methods were used the inductive – deductive, analysis and synthesis and comparative. As empiric method was used the bibliographic research. Results: Was made a conceptual disaggregation of touchablecost because of smoking to facility it accounting to be staring point to futures similar economic evaluations. Conclusions: Beginning of identify the smoking particularities like multicausal risk factor was made a general conceptual disaggregation of touchablecost because of smoking to facility since a social point of view, the smoking economic accounting.

Background: Once weekly (OW) semaglutide 0.5-1.0 mg is a glucagon-like type-1 receptor agonist (GLR-1 RA) approved for treatment of type 2 diabetes and is currently under evaluation for treatment of obesity at a higher dose of 2.4 mg OW. Objective: to provide an appraisal of WO semaglutide 2.4 mg for treatment of obesity. Methods: Pubmed research up to March 22. Randomized trials, pertinent animal studies, and reviews are included. Search terms were glucagon-like type 1 receptor agonists, weight loss, obesity, semaglutide, safety, efficacy. Results: WO semaglutide 2.4 mg was evaluated as a weight loss agent in 3 well-designed clinical trials of 68 week-duration. In one trial including patients with type 2 diabetes, the difference in weight loss from baseline to week 68 between OW semaglutide and placebo was - 6.2 percentage points (95% CI, -7.3 to -5.2; P<0.0001). In the other 2 studies that excluded patients with diabetes, the difference in weight loss between OW semaglutide and placebo ranged between -10.3% and -12.4%. A significantly higher proportion of participants in the semaglutide groups vs placebo groups achieved at least 5% of weight loss. The most common adverse effects of semaglutide were related to the gastrointestinal (GI) system. Across these 3 trials, premature discontinuation of OW semaglutide occurred in 6-7% vs 3% in placebo groups. Conclusions: OW semaglutide may be a promising agent for treatment of obesity irrespective of presence of type 2 diabetes. Further studies are needed to establish its long-term safety and efficacy.

The existence of antibiotic residues in edible products constitutes a health problem to the consumers. Reversed-phase high-performance liquid chromatography with diode array detection (HPLC–DAD) was optimized and validated for the simultaneous determination of florfenicol (FF), penicillin (PE), and tetracycline (TC) residues in dairy raw milk samples. The determination of these antibiotics was carried out on HP-ODS Hypersil C18 (5µm, 125*4 mm) column at a flow rate (1mL/min) and temperature (35 °C). The extraction method includes deproteinization of the milk sample followed by a solid-phase extraction (SPE) clean-up. The method was validated according to the European Commission Decision 2002/657/EC and the International Conference of Harmonization Guidelines. The recoveries for the studied antibiotics ranged from 82–111.54 % making the method suitable for performing routine analysis. The proposed method was applied for the analysis of antibiotic residues in 50 dairy raw milk samples collected from many regions in Lebanon. The results showed the occurrence of these antibiotics residues in milk collected from different Lebanese regions. The numbers indicate that 22 % of milk samples were found to be positive for FF, 42 % for PE, and 28 % for TC residues.

Introduction: The objective of this study is to compare the outcomes of Modified Desarda repair no mesh and Lichtenstein repair for inguinal hernia. Methods: This is a prospective randomized controlled trial study of 1342 patients having 1394 hernias operated from January 2008 to December 2020. 690 patients were operated using Lichtenstein repair and 652 using Desarda repair. The demographie data (Age,Sex) , hernia type and location , anesthetic , operative time , postoperative pain and complications were analysed. Results: There were no significant differences regarding age, sex, location, type of hernia, and pain in both the groups. The operation time was 52 minutes in Modified Desarda group and 42 minutes in the Lichtenstein group that is significant (p<0.05). The recurrence was 0.0 % in Modified Desarda group and 0.28 % in Lichtenstein group. But, there were 9 cases of infection to the polypropylene mesh in the Lichtenstein group, 2 of this required re-exploration. The morbidity was also significantly more in Lichtenstein group (7,6 %) as compared to Modified Desarda group (3.8 %). The mean time to return to work in the Modified Desarda group was 8.26 days while a mean of 12.58 days was in the Lichtenstein group. The mean hospital stay was 29 hrs. in Modified Desarda group while it was 49 hours in the Lichtenstein group in those patients who were hospitalized. Conclusions: The modified Desarda repair scores significantly on Lichtenstein repair in most of all aspects, including reexplorations and morbidity. Modified Desarda repair is a better option compared to Lichtenstein repair.